Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept + JAK Inhibitor in Refractory RA
NCT05451615Phase 3Unknown
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rheumatoid arthritis (RA) (2 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Efficacy of Abatacept Combined With JAK Inhibitor at 1 year. Status: unknown.
02
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05451615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451615.